| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10914654 | Molecular Oncology | 2015 | 7 Pages |
Abstract
KRAS mutation indicates poor prognosis. FOLFOX adjuvant chemotherapy benefits patients with stage II or III colorectal cancer with KRAS mutant tumors and is worth further investigation.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Yanhong Deng, Li Wang, Shuyun Tan, George P. Kim, Ruoxu Dou, Dianke Chen, Yue Cai, Xinhui Fu, Lei Wang, Jun Zhu, Jianping Wang,